Gemphire to Present at Two Investor Conferences
09 March 2018 - 12:00AM
Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage
biopharmaceutical company focused on developing and commercializing
therapies for cardiometabolic disorders, including dyslipidemia,
non-alcoholic fatty liver disease (NAFLD) and nonalcoholic
steatohepatitis (NASH), today announced that management will be
making presentations at the 30th Annual ROTH Conference and the
H.C. Wainwright 2nd Annual NASH Investor Conference.
Presentation Details30th Annual ROTH
Conference |
Date:Time:Panel:Panelist:Location: |
|
Tuesday,
March 137am Pacific Time/10am Eastern TimeIt Is Not a Myth, It Is
Real: Pediatric NASHSeth Reno, Chief Commercial OfficerRitz
Carlton, Laguna Niguel, California |
|
|
|
Date:Time:Panel:Panelist:Location: |
|
Tuesday,
March 138am Pacific Time/11am Eastern TimeLove Your Liver, Love
Your Heart: Cardio-Metabolic MoleculesSteve Gullans, Ph.D.,
Interim Chief Executive OfficerRitz Carlton, Laguna Niguel,
California |
|
|
|
H.C. Wainwright 2nd Annual NASH Investor
Conference |
Date:Time:Presenter:Location:Webcast: |
|
Monday,
March 198:40am Eastern TimeSteve Gullans, Ph.D., Interim Chief
Executive OfficerSt. Regis Hotel, New York
Cityhttp://wsw.com/webcast/hcw3/gemp/ |
|
|
|
About GemphireGemphire is a
clinical-stage biopharmaceutical company that is committed to
helping patients with cardiometabolic disorders, including
dyslipidemia and NASH. The Company is focused on providing
new treatment options for cardiometabolic diseases through its
complementary, convenient, cost-effective product candidate
gemcabene as add-on to the standard of care, especially statins,
that will benefit patients, physicians, and payors.
Gemphire’s Phase 2 clinical program is evaluating the efficacy and
safety of gemcabene in hypercholesterolemia, including FH and
ASCVD, SHTG and NASH/NAFLD. Two trials supporting
hypercholesterolemia have been completed under NCT02722408 and
NCT02634151. Gemphire has completed recruitment for a
clinical trial for SHTG under NCT02944383, and has initiated
separate trials for adult NASH and pediatric NAFLD. Please visit
www.gemphire.com for more information.
Contact:Andrew McDonald, Ph.D.LifeSci Advisors,
LLC(646) 597-6987
Jeff Mathiesen, CFOGemphire Therapeutics Inc.(734)-245-1700
Gemphire Therapeutics (NASDAQ:GEMP)
Historical Stock Chart
From Apr 2024 to May 2024
Gemphire Therapeutics (NASDAQ:GEMP)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Gemphire Therapeutics Inc (NASDAQ): 0 recent articles
More News Articles